Product Name

  • Name

    Sodium 2-propylpentanoate

  • EINECS 213-961-8
  • CAS No. 1069-66-5
  • Article Data8
  • CAS DataBase
  • Density 1.0803 g/cm3
  • Solubility water: 50 mg/mL
  • Melting Point 300 °C
  • Formula C8H15NaO2
  • Boiling Point 220 °C at 760 mmHg
  • Molecular Weight 166.196
  • Flash Point 116.6 °C
  • Transport Information
  • Appearance White solid
  • Safety 36/37-53-45-37/39-26-36
  • Risk Codes 22-61-36/38-36/37/38
  • Molecular Structure Molecular Structure of 1069-66-5 (Sodium 2-propylpentanoate)
  • Hazard Symbols HarmfulXn,ToxicT,IrritantXi
  • Synonyms Pentanoicacid, 2-propyl-, sodium salt (9CI);Valeric acid, 2-propyl-, sodium salt(7CI,8CI);Acediprol;Convulex;Depacon;Depakene;Depakene R;Depakene syrup8;Depakin;Depakine chronosphere;Dipropylacetate sodium;Epilim;KW 6066N;Micropakine LP;Orfiril;Selenica R;Sodium 2-propylpentanoate;Sodium2-propylvalerate;Sodium bispropylacetate;Sodium dipropylacetate;Sodiumvalproate;Sodium a,a-dipropylacetate;Valerin;Valproate sodium;Valpron;Vupral;2-Propylpentanoic acid sodium salt;
  • PSA 40.13000
  • LogP 0.95270

Synthetic route

valproic acid
99-66-1

valproic acid

sodium valproate
1069-66-5

sodium valproate

Conditions
ConditionsYield
With sodium hydroxide In water Product distribution / selectivity;100%
With sodium hydroxide In water at 20℃;100%
With sodium hydroxide In toluene97.7%
With sodium hydroxide
ethyl 2-propylpentanoate
17022-31-0

ethyl 2-propylpentanoate

sodium valproate
1069-66-5

sodium valproate

Conditions
ConditionsYield
With methanol; sodium hydroxide for 9h; Time; Reflux; Large scale;87.2%
propyl bromide
106-94-5

propyl bromide

diethyl malonate
105-53-3

diethyl malonate

sodium valproate
1069-66-5

sodium valproate

Conditions
ConditionsYield
Stage #1: propyl bromide; diethyl malonate With sodium ethanolate In ethanol at 50℃; for 2h;
Stage #2: With sodium hydroxide In water at 60℃; for 3h;
Stage #3: at 110℃;
copper(II) choride dihydrate

copper(II) choride dihydrate

sodium valproate
1069-66-5

sodium valproate

Cu2(valproate)4
108558-25-4

Cu2(valproate)4

Conditions
ConditionsYield
In water for 24h;99%
[ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2
52462-29-0

[ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2

sodium valproate
1069-66-5

sodium valproate

[RuCl(κ2O-vpCO2)(η6-p-cymene)]

[RuCl(κ2O-vpCO2)(η6-p-cymene)]

Conditions
ConditionsYield
In methanol at 20℃; for 2h;96%
valproic acid
99-66-1

valproic acid

sodium valproate
1069-66-5

sodium valproate

divalproex sodium

divalproex sodium

Conditions
ConditionsYield
In acetonitrile Product distribution / selectivity; Heating / reflux;93.75%
In acetone at 50℃; for 0.166667h;
1,1'-(2,2'-dimethoxy-[1,1'-binaphthalene]-6,6'-diyl)bis(2-bromoethanone)

1,1'-(2,2'-dimethoxy-[1,1'-binaphthalene]-6,6'-diyl)bis(2-bromoethanone)

sodium valproate
1069-66-5

sodium valproate

(2,2'-dimethoxy-[1,1'-binaphthalene]-6,6'-diyl)bis(2-oxoethane-2,1-diyl) bis(2-propylpentanoate)

(2,2'-dimethoxy-[1,1'-binaphthalene]-6,6'-diyl)bis(2-oxoethane-2,1-diyl) bis(2-propylpentanoate)

Conditions
ConditionsYield
In acetonitrile at 20℃; for 4h;92%
sodium valproate
1069-66-5

sodium valproate

zinc(II) chloride
7646-85-7

zinc(II) chloride

zinc(II) valproate

zinc(II) valproate

Conditions
ConditionsYield
In water88%
sodium valproate
1069-66-5

sodium valproate

zinc(II) chloride
7646-85-7

zinc(II) chloride

[Zn2(valproate)4]

[Zn2(valproate)4]

Conditions
ConditionsYield
In water at 20℃;88%
sodium valproate
1069-66-5

sodium valproate

zinc(II) chloride
7646-85-7

zinc(II) chloride

[tetrakis-μ-2-propylpentanoatezinc(II)]

[tetrakis-μ-2-propylpentanoatezinc(II)]

Conditions
ConditionsYield
In water at 20℃; for 24h;88%
In water at 20℃; for 1h;
1-(4-chlorophenyl)-3-methyltriazene
20667-72-5, 20667-73-6, 40843-82-1

1-(4-chlorophenyl)-3-methyltriazene

sodium valproate
1069-66-5

sodium valproate

1-(4-chlorophenyl)-3-methyl-3-[2-(propyl)pentanoyl]triazene

1-(4-chlorophenyl)-3-methyl-3-[2-(propyl)pentanoyl]triazene

Conditions
ConditionsYield
Stage #1: sodium valproate With benzotriazol-1-ol In tetrahydrofuran at 20℃; for 0.25h;
Stage #2: With 1,1'-carbonyldiimidazole In tetrahydrofuran for 0.75h; Inert atmosphere;
Stage #3: 1-(4-chlorophenyl)-3-methyltriazene With sodium hydride; triethylamine In tetrahydrofuran; dichloromethane; mineral oil for 48h; Inert atmosphere;		87.2%
cobalt(II) chloride hexahydrate

cobalt(II) chloride hexahydrate

sodium valproate
1069-66-5

sodium valproate

[Co2(valporate)4]

[Co2(valporate)4]

Conditions
ConditionsYield
In water at 20℃;86.5%
cobalt(II) chloride hexahydrate

cobalt(II) chloride hexahydrate

sodium valproate
1069-66-5

sodium valproate

[Co2(valp)4]

[Co2(valp)4]

Conditions
ConditionsYield
In water at 20℃;86.5%
1H-imidazole
288-32-4

1H-imidazole

cadmium(II) chloride dihydrate

cadmium(II) chloride dihydrate

sodium valproate
1069-66-5

sodium valproate

Cd(valproate)2(imidazole)2

Cd(valproate)2(imidazole)2

Conditions
ConditionsYield
In methanol at 20℃; for 2h;86%
...Expand
1,10-Phenanthroline
66-71-7

1,10-Phenanthroline

cadmium(II) chloride dihydrate

cadmium(II) chloride dihydrate

sodium valproate
1069-66-5

sodium valproate

Cd(valproate)2(1,10-phenanthroline)H2O

Cd(valproate)2(1,10-phenanthroline)H2O

Conditions
ConditionsYield
In methanol at 20℃; for 2h;83%
...Expand
1,1'-(2,2'-dihydroxy-[1,1'-binaphthalene]-6,6'-diyl)bis(2-bromoethanone)

1,1'-(2,2'-dihydroxy-[1,1'-binaphthalene]-6,6'-diyl)bis(2-bromoethanone)

sodium valproate
1069-66-5

sodium valproate

Conditions
ConditionsYield
In acetonitrile at 20℃; for 4h;83%
(8S,9S,10R,13S,14S,17S)-17-((E)-1-(hydroxyimino)ethyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)one

(8S,9S,10R,13S,14S,17S)-17-((E)-1-(hydroxyimino)ethyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)one

sodium valproate
1069-66-5

sodium valproate

(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(2-propylpentanoyloxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
1364711-92-1

(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(2-propylpentanoyloxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; for 16h; Inert atmosphere;79%
(8S,9S,10R,13S,14S,17S)-17-((E)-1-(hydroxyimino)ethyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
1364709-15-8

(8S,9S,10R,13S,14S,17S)-17-((E)-1-(hydroxyimino)ethyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

sodium valproate
1069-66-5

sodium valproate

(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(2-propylpentanoyloxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
1364711-92-1

(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(2-propylpentanoyloxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Inert atmosphere;79%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Inert atmosphere;79%
cetylpyridinium chloride
123-03-5

cetylpyridinium chloride

sodium valproate
1069-66-5

sodium valproate

hexadecylpyridinium valproic acid
934544-54-4

hexadecylpyridinium valproic acid

Conditions
ConditionsYield
In water at 20℃; for 1h;77.14%
1,10-Phenanthroline
66-71-7

1,10-Phenanthroline

cobalt(II) chloride hexahydrate

cobalt(II) chloride hexahydrate

sodium valproate
1069-66-5

sodium valproate

Co(valproate)2(1,10-phenanthroline)H2O

Co(valproate)2(1,10-phenanthroline)H2O

Conditions
ConditionsYield
In methanol at 20℃; for 2h;76%
...Expand
1H-imidazole
288-32-4

1H-imidazole

cobalt(II) chloride hexahydrate

cobalt(II) chloride hexahydrate

sodium valproate
1069-66-5

sodium valproate

Co(valproate)2(imidazole)2

Co(valproate)2(imidazole)2

Conditions
ConditionsYield
In methanol at 20℃; for 2h;76%
...Expand
1,10-Phenanthroline
66-71-7

1,10-Phenanthroline

manganese (II) acetate tetrahydrate
6156-78-1

manganese (II) acetate tetrahydrate

sodium valproate
1069-66-5

sodium valproate

Mn(valproate)2(1,10-phenanthroline)H2O

Mn(valproate)2(1,10-phenanthroline)H2O

Conditions
ConditionsYield
In methanol at 20℃; for 2h;76%
...Expand
1H-imidazole
288-32-4

1H-imidazole

palladium diacetate
3375-31-3

palladium diacetate

sodium valproate
1069-66-5

sodium valproate

[Pd(valproate)2(imidazole)2]

[Pd(valproate)2(imidazole)2]

Conditions
ConditionsYield
In ethanol at 20℃; for 4h;75%
...Expand
ethanol
64-17-5

ethanol

diphenyltin(IV) dichloride
1135-99-5

diphenyltin(IV) dichloride

sodium valproate
1069-66-5

sodium valproate

6C8H15O2(1-)*6Sn(4+)*6C6H5(1-)*6O(2-)

6C8H15O2(1-)*6Sn(4+)*6C6H5(1-)*6O(2-)

Conditions
ConditionsYield
for 5h; Reflux;72%
...Expand
1,4-pyrazine
290-37-9

1,4-pyrazine

palladium diacetate
3375-31-3

palladium diacetate

sodium valproate
1069-66-5

sodium valproate

[Pd(valproate)2(pyrazine)2]

[Pd(valproate)2(pyrazine)2]

Conditions
ConditionsYield
In ethanol at 20℃; for 4h;72%
...Expand
sodium valproate
1069-66-5

sodium valproate

triphenyltin chloride
639-58-7

triphenyltin chloride

Ph3Sn(valproate)

Ph3Sn(valproate)

Conditions
ConditionsYield
In ethanol for 5h; Reflux;67%
trimethyltin(IV)chloride
1066-45-1

trimethyltin(IV)chloride

sodium valproate
1069-66-5

sodium valproate

Me3Sn(valproate)

Me3Sn(valproate)

Conditions
ConditionsYield
In ethanol for 5h; Reflux;62%
tributyltin chloride
1461-22-9

tributyltin chloride

sodium valproate
1069-66-5

sodium valproate

Bu3Sn(valproate)

Bu3Sn(valproate)

Conditions
ConditionsYield
In ethanol for 5h; Reflux;58%
sodium valproate
1069-66-5

sodium valproate

1-(4-carbamoylphenyl)-3-methyltriazene

1-(4-carbamoylphenyl)-3-methyltriazene

1-(4-carbamoylphenyl)-3-methyl-3-[2-(propyl)pentanoyl]triazene

1-(4-carbamoylphenyl)-3-methyl-3-[2-(propyl)pentanoyl]triazene

Conditions
ConditionsYield
Stage #1: sodium valproate With benzotriazol-1-ol In tetrahydrofuran at 20℃; for 0.25h;
Stage #2: With 1,1'-carbonyldiimidazole In tetrahydrofuran for 0.75h; Inert atmosphere;
Stage #3: 1-(4-carbamoylphenyl)-3-methyltriazene With sodium hydride; triethylamine In tetrahydrofuran; dichloromethane; mineral oil for 48h; Inert atmosphere;		56.2%
2-(bromomethyl)-4(3H)-quinazolinone
19062-51-2

2-(bromomethyl)-4(3H)-quinazolinone

sodium valproate
1069-66-5

sodium valproate

2-propylpentanoic acid 4-oxo-3,4-dihydroquinazolin-2-ylmethyl ester
1260163-35-6

2-propylpentanoic acid 4-oxo-3,4-dihydroquinazolin-2-ylmethyl ester

Conditions
ConditionsYield
In ethanol for 48h; Reflux;52%
1-(4-bromophenyl)-3-methyltriazene
40643-36-5

1-(4-bromophenyl)-3-methyltriazene

sodium valproate
1069-66-5

sodium valproate

1-(4-bromophenyl)-3-methyl-[2-(propyl)pentanoyl]triazene

1-(4-bromophenyl)-3-methyl-[2-(propyl)pentanoyl]triazene

Conditions
ConditionsYield
Stage #1: sodium valproate With benzotriazol-1-ol In tetrahydrofuran at 20℃; for 0.25h;
Stage #2: With 1,1'-carbonyldiimidazole In tetrahydrofuran for 0.75h; Inert atmosphere;
Stage #3: 1-(4-bromophenyl)-3-methyltriazene With sodium hydride; triethylamine In tetrahydrofuran; dichloromethane; mineral oil for 48h; Inert atmosphere;		46.1%

Sodium 2-propylpentanoate Specification

The IUPAC name of Sodium valproate is sodium 2-propylpentanoate. With the CAS registry number 1069-66-5, it is also named as 2-Propylpentanoic acid sodium salt. The product's categories are Valproic acid Series; Intermediates & Fine Chemicals; Pharmaceuticals; GABA/Glycine Receptor. Besides, it is white solid, which should be stored in sealed container in cool and dry place. In addition, its molecular formula is C8H15NaO2 and molecular weight is 166.19.

The other characteristics of Sodium valproate can be summarized as: (1)EINECS: 213-961-8; (2)ACD/LogP: 2.72; (3)# of Rule of 5 Violations: 0; (4)ACD/LogD (pH 5.5): 1.95; (5)ACD/LogD (pH 7.4): 0.16; (6)ACD/BCF (pH 5.5): 11.78; (7)ACD/BCF (pH 7.4): 1; (8)ACD/KOC (pH 5.5): 123.33; (9)ACD/KOC (pH 7.4): 2; (10)H bond acceptors: 2; (11)H bond donors: 1; (12)Freely Rotating Bonds: 5; (13)Polar Surface Area: 37.3 Å2; (14)Density: g/cm3; (15)Flash Point: 116.6 °C; (16)Melting point: 300 °C; (17)Solubility: H2O: 50 mg/mL; (18)Enthalpy of Vaporization: 50.29 kJ/mol; (19)Boiling Point: 220 °C at 760 mmHg; (20)Vapour Pressure: 0.0435 mmHg at 25 °C.

Preparation and Uses of Sodium valproate: it can be produced by Diethyl malonate. Furthermore, this chemical is an anticonvulsant which can be used in the treatment of epilepsy and bipolar disorder.

When you are using this chemical, please be cautious about it as the following: it is harmful if swallowed. And it is also irritating to eyes, respiratory system and skin. You should wear suitable protective clothing, gloves and eye / face protection. Moreover, this product may cause harm to the unborn child. Please avoid exposure - obtain special instructions before use. And in case of contact with eyes, please rinse immediately with plenty of water and seek medical advice. Additionally, in case of accident or if you feel unwell, please seek medical advice immediately (show the label whenever possible.) 

People can use the following data to convert to the molecule structure.
(1)SMILES:[Na+].[O-]C(=O)C(CCC)CCC
(2)InChI:InChI=1/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1
(3)InChIKey:AEQFSUDEHCCHBT-REWHXWOFAT
(4)Std. InChI:InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1
(5)Std. InChIKey:AEQFSUDEHCCHBT-UHFFFAOYSA-M

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LD50 intraperitoneal 565mg/kg (565mg/kg)   Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 13, Pg. 81, 1977.
child LDLo oral 750mg/kg (750mg/kg) BEHAVIORAL: COMA

CARDIAC: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: DYSPNEA		 Lancet. Vol. 1, Pg. 221, 1984.
child TDLo oral 1820mg/kg/12W (1820mg/kg) BEHAVIORAL: SLEEP

GASTROINTESTINAL: NAUSEA OR VOMITING		 Lancet. Vol. 2, Pg. 1110, 1980.
dog LD50 intraperitoneal 700mg/kg (700mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

BEHAVIORAL: TREMOR		 Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
dog LD50 oral 1420mg/kg (1420mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA

GASTROINTESTINAL: NAUSEA OR VOMITING		 Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
guinea pig LD50 oral 824mg/kg (824mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA		 Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
hamster LD50 oral 1740mg/kg (1740mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA		 Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
infant LDLo oral 250mg/kg/10D- (250mg/kg) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF ENDOCRINE PANCREAS

BLOOD: HEMORRHAGE		 Archives of Disease in Childhood. Vol. 58, Pg. 543, 1983.
man TDLo oral 17mg/kg (17mg/kg) BRAIN AND COVERINGS: OTHER DEGENERATIVE CHANGES

LIVER: LIVER FUNCTION TESTS IMPAIRED

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)		 Journal of Toxicology, Clinical Toxicology. Vol. 30, Pg. 209, 1992.
man TDLo oral 214mg/kg/30D- (214mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" Israel Journal of Medical Sciences. Vol. 30, Pg. 283, 1994.
mouse LD50 intramuscular 832mg/kg (832mg/kg)   Biochemical Pharmacology. Vol. 22, Pg. 1701, 1973.
mouse LD50 intraperitoneal 470mg/kg (470mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA		 Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
mouse LD50 intravenous 750mg/kg (750mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA		 Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 299, 1976.
mouse LD50 oral 977mg/kg (977mg/kg)   European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 25, Pg. 71, 1990.
mouse LD50 subcutaneous 860mg/kg (860mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

BEHAVIORAL: TREMOR		 Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
mouse LD50 unreported 1700mg/kg (1700mg/kg)   United States Patent Document. Vol. #3301754,
rabbit LD50 intraperitoneal 1200mg/kg (1200mg/kg)   Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 13, Pg. 81, 1977.
rabbit LD50 oral 1468mg/kg (1468mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 5, Pg. 41, 1971.
rat LD50 intraperitoneal 970mg/kg (970mg/kg) BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"		 Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
rat LD50 intravenous 509mg/kg (509mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 1155, 1983.
rat LD50 oral 670mg/kg (670mg/kg)   British Journal of Pharmacology. Vol. 74, Pg. 957P, 1981.
rat LD50 subcutaneous 1029mg/kg (1029mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 5, Pg. 41, 1971.
women TDLo oral 500mg/kg (500mg/kg) BEHAVIORAL: SLEEP

BEHAVIORAL: MUSCLE WEAKNESS		 Postgraduate Medical Journal. Vol. 62, Pg. 409, 1986.
women TDLo oral 1040mg/kg (1040mg/kg) BRAIN AND COVERINGS: CHANGES IN SURFACE EEG

BEHAVIORAL: COMA

BLOOD: THROMBOCYTOPENIA		 Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 279, 1995.

Related Products

Hot Products

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View